Womack Financial’s AbbVie ABBV Stock Holding History

Womack Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$823K	Sell	3,269 -49	-1%	-$10.5K	0.54%	36
2026 Q1	$722K	Sell	3,318 -31	-0.9%	-$6.88K	0.53%	40
2025 Q4	$765K	Buy	3,349 +1	+0%	+$228	0.57%	36
2025 Q3	$775K	Sell	3,348 -1	-0%	-$204	0.59%	35
2025 Q2	$622K	Buy	3,349 +9	+0.3%	+$1.67K	0.52%	37
2025 Q1	$700K	Sell	3,340 -23	-0.7%	-$4.47K	0.64%	34
2024 Q4	$598K	Buy	+3,363	New	+$618K	0.53%	36

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Womack Financial's ABBV Position: Q2 2026 in Review

Womack Financial reduced its AbbVie (ABBV) stake by 1.5% in Q2 2026, selling an estimated $10.5K and leaving 3,269 shares worth $823K. The position accounts for 0.54% of the portfolio, ranked #36.

Womack Financial first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Womack Financial held 3,269 shares of AbbVie worth $823K as of Q2 2026.
Womack Financial sold 49 AbbVie shares in Q2 2026, an estimated $10.5K.
AbbVie made up 0.54% of Womack Financial's portfolio in Q2 2026, its #36 holding.
Womack Financial first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Womack Financial's 13F filing for Q2 2026, filed 14 Aug 2026.